Description

The recombinant humanized anti-CD3 monoclonal antibody is a full-length IgG1 molecule produced in CHO stable cells, engineered to specifically engage the extracellular Ig-like domain of CD3ε chain, thereby inducing TCR-CD3 complex crosslinking and ITAM domain phosphorylation to activate PLCγ1-PKC-MAPK signaling cascades that overcome T-cell activation thresholds.

As a pivotal T-cell activator in ex vivo expansion systems, it drives naive T-cell differentiation into effector/memory phenotypes and sustains CAR-T cell clonal expansion through metabolic synergy with IL-2/IL-15, while its glycoengineered Fc domain eliminates FcγR-mediated cytokine storm risks.

In adoptive immunotherapy development, this antibody dynamically modulates CD28 costimulatory signaling to enhance tumor antigen reactivity of TIL products, suppresses Treg expansion, and validates CD3-targeted bispecific antibody (CD3xTarget) functionality during NK cell activation/expansion, establishing a versatile platform for solid/hematologic tumor immunotherapy.

Production employs animal component-free media and chromatographic purification to ensure ultra-low endotoxin levels and host protein contamination control, meeting comprehensive quality standards across cell therapy applications.

Specifications

Test Item	Specification	Results
Appearance	Should be a colorless and transparent liquid	Compliance
Identity	The electrophoretic bands should be consistent with the molecular weight of the product	Compliance
Visible Particle	Should be no visible particle	Compliance
pH	6.5 – 7.5	7.3
Concentration	1.0 – 1.5 mg/mL	1.04 mg/mL
Purity	>95.0%	98.8%
Endotoxin	<0.01 EU/μg	<0.01 EU/μg
Mycoplasma	Should be negative	Negative
Sterility	No growth	No growth
Host Cell Protein Residues (CHO-HCP)	≤100 ppm	1.23 ppm
Host Cell (CHO) DNA Remains	≤50 ng/mg	Not Detected
Biological Activity	Binding rate with Jurkat cells >90%	97.3%

Features

High-Specificity Targeting: Recognizes human CD3ε (epsilon) chain on T lymphocytes with high affinity, ideal for accurate T-cell identification.
Primary Monoclonal Antibody: Mouse-derived IgG1 primary antibody with consistent performance and lot integrity for research use.
Multi-Application Use: Validated for Flow Cytometry (FACS), Western Blot, ELISA, and Immunofluorescence, facilitating versatile immunological experiments.
Stable Formulation: Supplied in phosphate buffered saline (PBS) with stabilizers (BSA and sodium azide), optimized for long-term stability.
Research-Grade Quality: RUO (Research Use Only) antibody trusted by labs for immunophenotyping, T-cell activation studies, and cellular signaling research.

Applications

Flow Cytometry (FACS)

Flow Cytometry (FACS): Precise quantification and profiling of human CD3+ T cells in PBMCs and tissue samples.

Western Blot (WB)

Western Blot (WB): Detection of CD3ε protein expression in human cell lysates.

Immunofluorescence (IF)

Immunofluorescence (IF): Visualization of T-cell distribution and localization in cultured cells or tissue.

ELISA & Immunoassays

ELISA & Immunoassays: Analyzing CD3 presence or modulation in functional immunology studies.

T-Cell Activation & Signaling

T-Cell Activation & Signaling: Used in research to stimulate or monitor T-cell receptor interactions and downstream pathways.

Storage

Stable for up to 24 months when stored at 2-8°C under sterile condition.

Documents

📄 Data Sheet 📄 SDS 📄 COA

References

Silvia M Bacot, Taylor A Harper, Rebecca L Matthews, Christie Jane Fennell, Adovi Akue, Mark A KuKuruga, Shiowjen Lee, Tao Wang, Gerald M Feldman. Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy. Int J Mol Sci. 2020 Nov 27;21(23):9023.
Min Zhou, Jing Wang, Cui-Ping Li, Jing-Yan Xu, Bing Chen. Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission. Onco Targets Ther. 2020 Jun 22;13:5879-5885.

Attention

For research and manufacturing purposes only.

Anti-Human CD3 Monoclonal Antibody (CD3 Mab)